milrinone has been researched along with Atrioventricular Nodal Re-Entrant Tachycardia in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Milrinone infusion is one of a few select "non-device" therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation." | 7.96 | Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. ( Achu, E; Alpert, JS; Baran, DA; Cassuto, J; Goldschmidt, M; Harhash, AA; Hussein, A; Zucker, MJ, 2020) |
| "To evaluate the pharmocokinetics of intravenous milrinone in patients with severe congestive heart failure during continuous venovenous hemofiltration (CVVH)." | 7.70 | Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ( Matsumoto, H; Okeie, K; Saito, S; Shibata, K; Taniguchi, T, 2000) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 6.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 5.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "Milrinone infusion is one of a few select "non-device" therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation." | 3.96 | Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. ( Achu, E; Alpert, JS; Baran, DA; Cassuto, J; Goldschmidt, M; Harhash, AA; Hussein, A; Zucker, MJ, 2020) |
| "To evaluate the pharmocokinetics of intravenous milrinone in patients with severe congestive heart failure during continuous venovenous hemofiltration (CVVH)." | 3.70 | Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ( Matsumoto, H; Okeie, K; Saito, S; Shibata, K; Taniguchi, T, 2000) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 2.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Bacteremia was the most common type of infection." | 1.43 | Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy. ( Acharya, D; Hashim, T; Loyaga-Rendon, RY; Morgan, CJ; Pamboukian, SV; Revilla-Martinez, M; Sanam, K; Tallaj, JA, 2016) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 1.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laufer-Perl, M | 1 |
| Sadon, S | 1 |
| Zahler, D | 1 |
| Milwidsky, A | 1 |
| Sadeh, B | 1 |
| Sapir, O | 1 |
| Granot, Y | 1 |
| Korotetski, L | 1 |
| Ketchker, L | 1 |
| Rosh, M | 1 |
| Banai, S | 1 |
| Havakuk, O | 1 |
| Harhash, AA | 1 |
| Cassuto, J | 1 |
| Hussein, A | 1 |
| Achu, E | 1 |
| Zucker, MJ | 1 |
| Goldschmidt, M | 1 |
| Alpert, JS | 1 |
| Baran, DA | 1 |
| Cox, ZL | 1 |
| Calcutt, MW | 1 |
| Morrison, TB | 1 |
| Akers, WS | 1 |
| Davis, MB | 1 |
| Lenihan, DJ | 1 |
| Gurabi, Z | 2 |
| Koncz, I | 2 |
| Patocskai, B | 2 |
| Nesterenko, VV | 1 |
| Antzelevitch, C | 2 |
| Acharya, D | 1 |
| Sanam, K | 1 |
| Revilla-Martinez, M | 1 |
| Hashim, T | 1 |
| Morgan, CJ | 1 |
| Pamboukian, SV | 1 |
| Loyaga-Rendon, RY | 1 |
| Tallaj, JA | 1 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Mehra, MR | 1 |
| Ventura, HO | 1 |
| Kapoor, C | 1 |
| Stapleton, DD | 1 |
| Zimmerman, D | 1 |
| Smart, FW | 1 |
| Taniguchi, T | 1 |
| Shibata, K | 1 |
| Saito, S | 1 |
| Matsumoto, H | 1 |
| Okeie, K | 1 |
1 trial available for milrinone and Atrioventricular Nodal Re-Entrant Tachycardia
| Article | Year |
|---|---|
Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Drug Administration Schedule; Drug Ther | 1997 |
7 other studies available for milrinone and Atrioventricular Nodal Re-Entrant Tachycardia
| Article | Year |
|---|---|
Repetitive milrinone therapy in ambulatory advanced heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Huma | 2022 |
Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias.
Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Defibrillators, Implantable; Dose-Response Relationsh | 2020 |
Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction.
Topics: Adult; Aged; Cardiac Catheterization; Cardiotonic Agents; Creatinine; Defibrillators, Implantable; F | 2013 |
Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cilostazol; Disease Models, Animal; Dogs; Electr | 2014 |
Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy.
Topics: Administration, Intravenous; Adult; Aged; Alabama; Atrial Fibrillation; Bacteremia; Cardiotonic Agen | 2016 |
Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome.
Topics: Action Potentials; Animals; Cardiac Electrophysiology; Cardiovascular Agents; Cilostazol; Death, Sud | 2016 |
Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration.
Topics: Adult; Aged; Biological Availability; Female; Heart Failure; Hemodynamics; Hemofiltration; Humans; I | 2000 |